OrbusNeich has completed patient enrollment in a 180-patient trial of its Genous Bio-engineered R stent at 11 sites in China. OrbusNeich positions the Genous stent as an alternative to drug-eluting stents for patients who either do not respond to or cannot tolerate long-term dual antiplatelet therapy. Many of these patients have diabetes. The Genous sten has been available around the world since 2005. More details....